Role of Exenatide in Type 1 Diabetes

NCT00456300 on ClinicalTrials.gov · last registry update 2019-02-26

A small phase 2 — 11 participants, against a typical 110. Completed March 2009. exenatide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: Montefiore Medical Center
Sponsor type: Other
Enrollment: 11
Started: 2007-03
Primary completion: 2009-03 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Mean Plasma Glucose Area Under the Curve (AUC) for Blood Glucose Concentration in the Exenatide 1.25 mcg or Exenatide 2.5 mcg Treated Groups Along With Insulin, Compared to Insulin Alone

Conditions studied

Type 1 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.